Preclinical study reveals that a new vaccine may help to slow the progression of Alzheimer’s disease
The ability of our immune system to mount a well regulated defense against foreign substances including toxins weakens as we age, making vaccines less effective for people over 65. Research has also shown that immunotherapy targeting the neurotoxic forms (oligomeric ab) of the peptide beta amyloid may stop the progression of Alzheimer’s disease, which is the most common age related neurodegenerative disorder.
The team of Chuanhai Cao Ph.D. from the University of South Florida Health has been working to overcome inflammation, excessive immune system dysfunction, and other complications which interfere with the development of an Alzheimer’s therapeutic vaccine.
A preclinical study conducted by Dr. Cao, along with his colleagues, indicates that a dendritic antigen-presenting vaccine with a specific response to oligomeric Ab could be safer and provide clinical benefits in the treatment of Alzheimer’s. The vaccine E22W42 DC uses immune cells called dendritic (DC) that are loaded with a modified Ab as the antigen.